Jason N. Rosenbaum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jason N. Rosenbaum has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Carla Wilson
2 shared publicationsChristine Gibson
2 shared publicationsDennis P. O'Malley
2 shared publications- Eric J. Duncavage
Department of Pathology and Immunology, Washington University, St. Louis, Missouri
2 shared publications Joseph D. Khoury
2 shared publicationsKeyur P. Patel
2 shared publications
Latest Publications
- 1 November 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 6 (6) , e2200454
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit
PURPOSE: Immune checkpoint inhibition (ICI) therapy represents one of the great advances in the field of oncology, highlighted by the Nobel Prize in 2018. Multiple predictive biomarkers for ICI benefit have been proposed. These include assessment of programmed death ligand-1 expression by immunohistochemistry, and determination of mutational genotype (microsatellite instability or mismatch repair deficiency or tumor mutational burden) as a reflection of neoantigen expression. However, deployment of these assays has been challenging for oncologists and pathologists alike.METHODS: To address these issues, ASCO and the College of American Pathologists convened a virtual Predictive Factor Summit from September 14 to 15, 2021. Representatives from the academic community, US Food and Drug Administration, Centers for Medicare and Medicaid Services, National Institutes of Health, health insurance organizations, pharmaceutical companies, in vitro diagnostics manufacturers, and patient advocate organizations presented state-of-the-art predictive factors for ICI, associated problems, and possible solutions.RESULTS: The Summit provided an overview of the challenges and opportunities for improvement in assay execution, interpretation, and clinical applications of programmed death ligand-1, microsatellite instability-high or mismatch repair deficient, and tumor mutational burden-high for ICI therapies, as well as issues related to regulation, reimbursement, and next-generation ICI biomarker development.CONCLUSION: The Summit concluded with a plan to generate a joint ASCO/College of American Pathologists strategy for consideration of future research in each of these areas to improve tumor biomarker tests for ICI therapy.
- 1 November 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 6 (6) , e2200454
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit
PURPOSE: Immune checkpoint inhibition (ICI) therapy represents one of the great advances in the field of oncology, highlighted by the Nobel Prize in 2018. Multiple predictive biomarkers for ICI benefit have been proposed. These include assessment of programmed death ligand-1 expression by immunohistochemistry, and determination of mutational genotype (microsatellite instability or mismatch repair deficiency or tumor mutational burden) as a reflection of neoantigen expression. However, deployment of these assays has been challenging for oncologists and pathologists alike.METHODS: To address these issues, ASCO and the College of American Pathologists convened a virtual Predictive Factor Summit from September 14 to 15, 2021. Representatives from the academic community, US Food and Drug Administration, Centers for Medicare and Medicaid Services, National Institutes of Health, health insurance organizations, pharmaceutical companies, in vitro diagnostics manufacturers, and patient advocate organizations presented state-of-the-art predictive factors for ICI, associated problems, and possible solutions.RESULTS: The Summit provided an overview of the challenges and opportunities for improvement in assay execution, interpretation, and clinical applications of programmed death ligand-1, microsatellite instability-high or mismatch repair deficient, and tumor mutational burden-high for ICI therapies, as well as issues related to regulation, reimbursement, and next-generation ICI biomarker development.CONCLUSION: The Summit concluded with a plan to generate a joint ASCO/College of American Pathologists strategy for consideration of future research in each of these areas to improve tumor biomarker tests for ICI therapy.
- 1 October 2021
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 23 (10) , 1218-1240
A Curriculum for Genomic Education of Molecular Genetic Pathology Fellows
- 1 October 2021
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 23 (10) , 1218-1240
A Curriculum for Genomic Education of Molecular Genetic Pathology Fellows
- 17 April 2019
- Published by S. Karger AG in Acta Cytologica
- Vol. 64 (1-2) , 147-154
Development and Validation of Molecular Assays for Limited Tissue Samples
As the value of molecular testing of cancer specimens increases, the number of tests imposed on tumor specimens also increases, often in tension with the amount of tumor material available. To develop and validate molecular assays for limited specimens, there are specific concerns that must be addressed, including DNA quality, quantity, and abundance; the number of targets/ability to multiplex; and the analytical sensitivity and specificity of the assay itself. Ultimately, weighing these considerations during assay validation in the overall context of clinical utility and laboratory workflow is critical for delivering the highest level of personalized care to patients.
- 17 April 2019
- Published by S. Karger AG in Acta Cytologica
- Vol. 64 (1-2) , 147-154
Development and Validation of Molecular Assays for Limited Tissue Samples
As the value of molecular testing of cancer specimens increases, the number of tests imposed on tumor specimens also increases, often in tension with the amount of tumor material available. To develop and validate molecular assays for limited specimens, there are specific concerns that must be addressed, including DNA quality, quantity, and abundance; the number of targets/ability to multiplex; and the analytical sensitivity and specificity of the assay itself. Ultimately, weighing these considerations during assay validation in the overall context of clinical utility and laboratory workflow is critical for delivering the highest level of personalized care to patients.
- 1 December 2018
- Published by Elsevier in Cancer Genetics
- Vol. 228-229, 55-63
Validation of a next-generation sequencing oncology panel optimized for low input DNA
- 1 December 2018
- Published by Elsevier in Cancer Genetics
- Vol. 228-229, 55-63
Validation of a next-generation sequencing oncology panel optimized for low input DNA
- 1 May 2018
- Published by Elsevier in Laboratory Investigation
- Vol. 31 (5) , 791-808
Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer
- 1 May 2018
- Published by Elsevier in Laboratory Investigation
- Vol. 31 (5) , 791-808
Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer
- 17 November 2017
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 45 (2) , 129-135
Insulinoma‐associated 1: A novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma)
Merkel cell carcinoma (MCC) is a rare, clinically aggressive, cutaneous neuroendocrine (NE) neoplasm. As a tumor with small, round, blue cells, the histologic differential diagnosis for MCC can include melanoma, metastatic small cell carcinoma (SCC), nodular hematopoietic tumors, basal cell carcinoma (BCC), atypical variants of squamous carcinoma and the uncommon occurrence of primary cutaneous Ewing sarcoma. In cases with atypical histology or without the classic immunophenotype, the diagnosis can be challenging. Ultimately, immunohistochemistry (IHC) is essential to the definitive diagnosis of MCC and in difficult cases, the diagnosis may hinge entirely on the immunophenotype of the tumor cells. Insulinoma‐associated 1 (INSM1) is a transcription factor expressed in tissues undergoing terminal NE differentiation. As a nuclear protein tied to both differentiation and the cell cycle, INSM1 may offer additional utility in comparison to traditional, cytoplasmic markers of NE differentiation.
- 17 November 2017
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 45 (2) , 129-135
Insulinoma‐associated 1: A novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma)
Merkel cell carcinoma (MCC) is a rare, clinically aggressive, cutaneous neuroendocrine (NE) neoplasm. As a tumor with small, round, blue cells, the histologic differential diagnosis for MCC can include melanoma, metastatic small cell carcinoma (SCC), nodular hematopoietic tumors, basal cell carcinoma (BCC), atypical variants of squamous carcinoma and the uncommon occurrence of primary cutaneous Ewing sarcoma. In cases with atypical histology or without the classic immunophenotype, the diagnosis can be challenging. Ultimately, immunohistochemistry (IHC) is essential to the definitive diagnosis of MCC and in difficult cases, the diagnosis may hinge entirely on the immunophenotype of the tumor cells. Insulinoma‐associated 1 (INSM1) is a transcription factor expressed in tissues undergoing terminal NE differentiation. As a nuclear protein tied to both differentiation and the cell cycle, INSM1 may offer additional utility in comparison to traditional, cytoplasmic markers of NE differentiation.
- 1 October 2017
- Published by Elsevier in The American Journal of Pathology
- Vol. 187 (10) , 2185-2198
The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics
- 1 October 2017
- Published by Elsevier in The American Journal of Pathology
- Vol. 187 (10) , 2185-2198
The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics
- 15 April 2016
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 140 (11) , 1225-1227
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Article Citation: Eric Duncavage, Ranjana H. Advani, Steven Agosti, Philip Foulis, Christine Gibson, Loveleen Kang, Joseph D. Khoury, L. Jeffrey Medeiros, Robert S. Ohgami, Dennis P. O'Malley, Keyur P. Patel, Jason N. Rosenbaum, Carla Wilson, and for the Members of the Cancer Biomarker Reporting Committee, College of American Pathologists (2016) Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Archives of Pathology & Laboratory Medicine: November 2016, Vol. 140, No. 11, pp. 1225-1227. https://doi.org/10.5858/arpa.2015-0418-CP
- 15 April 2016
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 140 (11) , 1225-1227
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Article Citation: Eric Duncavage, Ranjana H. Advani, Steven Agosti, Philip Foulis, Christine Gibson, Loveleen Kang, Joseph D. Khoury, L. Jeffrey Medeiros, Robert S. Ohgami, Dennis P. O'Malley, Keyur P. Patel, Jason N. Rosenbaum, Carla Wilson, and for the Members of the Cancer Biomarker Reporting Committee, College of American Pathologists (2016) Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Archives of Pathology & Laboratory Medicine: November 2016, Vol. 140, No. 11, pp. 1225-1227. https://doi.org/10.5858/arpa.2015-0418-CP
- 15 April 2016
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 140 (11) , 1228-1230
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Article Citation: Eric Duncavage, Ranjana H. Advani, Steven Agosti, Philip Foulis, Christine Gibson, Loveleen Kang, Joseph D. Khoury, L. Jeffrey Medeiros, Robert S. Ohgami, Dennis P. O'Malley, Keyur P. Patel, Jason N. Rosenbaum, Carla Wilson, and for the Members of the Cancer Biomarker Reporting Committee, College of American Pathologists (2016) Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Archives of Pathology & Laboratory Medicine: November 2016, Vol. 140, No. 11, pp. 1228-1230. https://doi.org/10.5858/arpa.2016-0045-CP
- 15 April 2016
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 140 (11) , 1228-1230
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Article Citation: Eric Duncavage, Ranjana H. Advani, Steven Agosti, Philip Foulis, Christine Gibson, Loveleen Kang, Joseph D. Khoury, L. Jeffrey Medeiros, Robert S. Ohgami, Dennis P. O'Malley, Keyur P. Patel, Jason N. Rosenbaum, Carla Wilson, and for the Members of the Cancer Biomarker Reporting Committee, College of American Pathologists (2016) Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Archives of Pathology & Laboratory Medicine: November 2016, Vol. 140, No. 11, pp. 1228-1230. https://doi.org/10.5858/arpa.2016-0045-CP
- Open Access
- 1 October 2015
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 144 (4) , 579-591
INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms
Objectives:. Neuroendocrine neoplasms (NENs) are heterogeneous neoplasms, which are sometimes malignant, although predicting metastasis is difficult. I
- 1 October 2015
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 144 (4) , 579-591
Open AccessINSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms
Objectives:. Neuroendocrine neoplasms (NENs) are heterogeneous neoplasms, which are sometimes malignant, although predicting metastasis is difficult. I